DNTH
Dianthus Therapeutics, Inc. NASDAQ$87.42
Mkt Cap $3.3B
52w Low $16.64
88.6% of range
52w High $96.50
50d MA $77.26
200d MA $46.29
P/E (TTM)
-20.8x
EV/EBITDA
-8.5x
P/B
6.7x
Debt/Equity
0.0x
ROE
-32.9%
P/FCF
-12.0x
RSI (14)
—
ATR (14)
—
Beta
0.21
50d MA
$77.26
200d MA
$46.29
Avg Volume
976.7K
About
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. D…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.98 | -1.43 | -45.9% | 79.23 | +2.3% | +9.7% | +8.3% | +1.4% | -1.7% | -1.6% | +10.4% | — |
| Nov 5, 2025 | AMC | -0.86 | -0.97 | -12.8% | 33.73 | +0.4% | +8.0% | +7.6% | +8.5% | +7.0% | +14.8% | +31.2% | — |
| Aug 7, 2025 | AMC | -0.86 | -0.88 | -2.3% | 19.15 | -0.8% | -2.0% | -1.4% | +3.9% | +8.9% | +5.7% | +66.1% | — |
| May 12, 2025 | AMC | -0.86 | -0.82 | +4.7% | 20.08 | -2.6% | -6.2% | -5.9% | -6.6% | -1.9% | -4.0% | -9.8% | — |
| Mar 11, 2025 | AMC | -0.85 | -0.81 | +4.7% | 23.38 | -6.5% | -6.3% | -9.0% | -8.8% | -6.0% | -11.3% | -33.3% | — |
| Nov 7, 2024 | AMC | -0.59 | -0.74 | -25.4% | 29.90 | +7.9% | -2.8% | -7.2% | -7.4% | -11.9% | -14.7% | -18.9% | — |
| Aug 8, 2024 | AMC | -0.50 | -0.51 | -2.0% | 26.74 | +1.0% | +2.8% | -1.0% | -1.0% | +6.6% | +11.5% | +4.2% | — |
| May 9, 2024 | AMC | -0.43 | -0.54 | -25.6% | 24.93 | +6.2% | -2.6% | +4.3% | +12.1% | +11.1% | +5.3% | -13.9% | — |
| Mar 21, 2024 | AMC | -1.11 | -0.71 | +36.0% | 27.94 | +6.0% | +14.3% | +10.9% | +12.8% | +9.5% | +7.4% | -16.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -3.78 | -641.2% | 11.41 | +0.8% | +0.8% | -0.5% | -0.9% | +1.7% | +0.4% | -28.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $85.84 | $85.53 | -0.4% | -6.4% | -9.3% | -9.1% | -8.1% | -8.1% |
| Mar 10 | Baird | Maintains | Outperform → Outperform | — | $79.23 | $81.08 | +2.3% | +9.7% | +8.3% | +1.4% | -1.7% | -1.6% |
| Mar 10 | Clear Street | Maintains | Buy → Buy | — | $79.23 | $81.08 | +2.3% | +9.7% | +8.3% | +1.4% | -1.7% | -1.6% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $79.23 | $81.08 | +2.3% | +9.7% | +8.3% | +1.4% | -1.7% | -1.6% |
| Mar 10 | Raymond James | Upgrade | Outperform → Strong Buy | — | $79.23 | $81.08 | +2.3% | +9.7% | +8.3% | +1.4% | -1.7% | -1.6% |
| Mar 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $65.20 | $78.90 | +21.0% | +21.5% | +33.3% | +31.7% | +23.2% | +19.4% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.20 | $78.90 | +21.0% | +21.5% | +33.3% | +31.7% | +23.2% | +19.4% |
| Mar 9 | Truist | Maintains | Buy → Buy | — | $65.20 | $78.90 | +21.0% | +21.5% | +33.3% | +31.7% | +23.2% | +19.4% |
| Mar 4 | Guggenheim | Maintains | Buy → Buy | — | $55.39 | $58.45 | +5.5% | +12.0% | +10.9% | +17.7% | +43.0% | +56.9% |
| Feb 11 | Wedbush | Maintains | Outperform → Outperform | — | $50.82 | $50.86 | +0.1% | -1.8% | -6.6% | -6.7% | -3.2% | -6.6% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Dianthus is presenting corporate strategy details, likely including pipeline updates for lead candidates Claseprubart and DNTH212, which investors should monitor for clinical progress or commercialization timeline clarity.
Mar 26
8-K
Unknown — 8-K Filing
DNTH issued pre-funded warrants allowing holders to accumulate up to 19.99% ownership with 61-day notice, indicating significant dilution risk and potential control shifts for existing shareholders.
Mar 12
8-K · 8.01
!! High
Dianthus Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Dianthus Therapeutics advanced claseprubart to Phase 3 following positive interim data in its CIDP trial, signaling regulatory confidence and potential path toward approval for this neuropathy treatment.
Mar 9
Data updated apr 25, 2026 5:32am
· Source: massive.com